endpoint, a provider of Integrated Voice Response (IVR) and Integrated Web Response (IWR) systems, announced today its expansion into Europe with a European HQ office expected to open in early 2014.
endpoint
, a provider of Integrated Voice Response (IVR) and Integrated Web Response (IWR) systems, announced today its expansion into Europe with a European HQ office expected to open in early 2014. endpoint has doubled its revenue in the past two years and is forecasted to grow 40 percent in 2014.
endpoint is currently working on clinical trials in 40+ countries and the global expansion is seen as a natural progression for the company.
“It has long been our plan with our growing customer base in the Americas and Europe to add more resources in Europe.” said Jonathan Dole, co-founder and CEO, endpoint. “Not only is this a milestone for endpoint, but it also supports our growing European customer base.”
endpoint recently recruited Garrath Read as Director of Global Business Development, to support endpoint’s growth in Europe. Garrath comes from a global CRO background with over 15 years sales/healthcare experience.
“endpoint has been in the enviable position of meeting customers’ needs with a solution that can be implemented significantly faster than any of its competitors ,” said Garrath. “I’m very pleased to work for a company whose sole purpose is to create more efficient clinical trials with the patient being the winner.”
endpoint’s flagship product platform, PULSE, is fully configurable, allowing users to design and deploy clinical trial Integrated Response Technology (IRT) systems while saving 40 percent on the development time of clinical trials.
Endpoint will be exhibiting at the 12th annual Partnerships in Clinical Trials Congress in Vienna, Austria on the 20th-21st of November.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.